Topics
Low-grade gliomas | Treatment | Targeted therapy | Vorasidenib
Home > Publications > Topics > Low-grade gliomas > Treatment > Targeted terapy > Vorasidenib
*Silvani A, Franceschi E.
A
new era after a long wait: Vorasetinib, an inhibitor of mutant
IDH1 and IDH2 enzymes in patients with IDH-mutant glioma.
Tumori.
2024 Jan 2:3008916231217583. doi:
10.1177/03008916231217583. PMID:
38166539. Editorial. ˍ
Related
article:
Mellinghoff
IK, van den Bent MJ, Blumenthal DT, et al.
Vorasidenib
in IDH1- or IDH2-Mutant Low-Grade Glioma.
N
Engl J Med.
2023 Jun 4. doi:
10.1056/NEJMoa2304194. PMID:
37272516. Interventional study. ˍ
Gatto L, Di Nunno V, Tosoni A,
Bartolini S, Ranieri L, Franceschi E.
Vorasidenib
in IDH1/2-mutant low-grade glioma: the grey zone of patient's
selection.
Front
Oncol. 2024 Jan
11;13:1339266. doi:
10.3389/fonc.2023.1339266. PMID:
38273856. Comment. ˍ
Related
article:
Mellinghoff
IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J,
Mendez J, Yust-Katz S, Welsh L, Mason WP, Ducray F, Umemura Y,
Nabors B, Holdhoff M, Hottinger AF, Arakawa Y, Sepulveda JM, Wick
W, Soffietti R, Perry JR, Giglio P, de la Fuente M, Maher EA,
Schoenfeld S, Zhao D, Pandya SS, Steelman L, Hassan I, Wen PY,
Cloughesy TF.
Vorasidenib
in IDH1- or IDH2-Mutant Low-Grade Glioma.
N
Engl J Med.
2023 Jun 4. doi:
10.1056/NEJMoa2304194. PMID:
37272516. Interventional study. ˍ
Rudà R, Horbinski C, van den Bent M, Preusser M, Soffietti
R.
IDH inhibition in gliomas: from
preclinical models to clinical trials.
Nat
Rev Neurol. 2024 May 17. doi:
10.1038/s41582-024-00967-7. PMID:
38760442. Review. ˍ
Lazarev S, Sindhu KK.
Vorasidenib: a
new hope or a false promise for patients with low-grade glioma?
Nat
Rev Clin Oncol. 2024 Sep 12. doi:
10.1038/s41571-024-00944-5. PMID:
39266767. Perspective˰
ˍ
Malik H, Hudaib M, Rehman A.
Vorasidenib-
A Paradigm Shift in IDH1- or IDH2-Mutant Low-Grade Glioma
Treatment.
J
Pak Med Assoc. 2024 Sep 21;74(10):1912-1913. doi:
10.47391/JPMA.20428. PMID:
39407401. Perspective. ˍ
Tom MC, Nagpal S, Palmer JD, Breen WG, Pollom EL, Lehrer EJ,
McGranahan TM, Shiue K, Chundury A, McClelland Iii S, Saeed H,
Chang EL, Chiang VLS, Wang TJC, Knisely JPS, Chao ST, Milano MT.
An update to the American Radium
Society's appropriate
use criteria of lower grade gliomas: Integration of IDH
inhibitors.
Radiother
Oncol. 2024 Nov 16;202:110640. doi:
10.1016/j.radonc.2024.110640. PMID:
39557126. Recommendations˰
ˍ